Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities

CNS Neuroscience and Therapeutics

Volumn 20, Issue 7, 2014, Pages 613-623

  Nikolic, Katarina ^a   Filipic, Slavica ^a   Agbaba, Danica ^a   Stark, Holger ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

AChE; HMT; Pharmacophore; Procognitive; SERT

Indexed keywords

ACETYLCHOLINESTERASE; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE METHYLTRANSFERASE; SEROTONIN TRANSPORTER; HISTAMINE H3 RECEPTOR; NOOTROPIC AGENT; SEROTONIN 3 ANTAGONIST;

COGNITION; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG TARGETING; ENZYME INHIBITION; INVERSE AGONISM; MENTAL DISEASE; NEUROTRANSMISSION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; PROCEDURES;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NOOTROPIC AGENTS; RECEPTORS, HISTAMINE H3; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 84902546230     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12279     Document Type: Review

References (142)

1. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev 1991;71:1-51.
2. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001;63:637-672.
3. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302:832-837.
4. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008;88:1183-1241.
5. Panula P, Yang HY, Costa E. Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci USA 1984;81:2572-2576.
6. 4 receptor: Targeting inflammatory diseases. Eur J Pharmacol 2011;668:1-5.
7. 4 receptor ligands and their potential therapeutic applications: An update. Expert Opin Ther Pat 2012;22:205-221.
8. Watanabe T, Taguchi Y, Shiosaka S, et al. Distribution of the histaminergic neuron system in the central nervous system of rats: A fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. Brain Res 1984;295:13-25.
9. Pillot C, Heron A, Cochois V, et al. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 2002;114:173-193.
10. Cecchi M, Giorgetti M, Bacciottini L, Giovannini MG, Blandina P. Increase of acetylcholine release from cortex of freely moving rats by administration of histamine into the nucleus basalis magnocellularis. Inflamm Res 1998;47:S32-S33.
11. Philippu A, Prast H. Importance of histamine in modulatory processes, locomotion and memory. Behav Brain Res 2001;124:151-159.
12. Kraus MM, Fischer H, Tran MH, Philippu A, Prast H. Modulation of acetylcholine release by histamine in the nucleus accumbens. Inflamm Res 2001;50:S74-S75.
13. Blandina P, Efoudebe M, Cenni G, Mannaioni P, Passani MB. Acetylcholine, histamine, and cognition: Two sides of the same coin. Learn Mem 2004;11:1-8.
14. 3 receptors. Naunyn Schmiedebergs Arch Pharmacol 1989;340:633-638.
15. Korotkova TM, Sergeeva OA, Ponomarenko AA, Haas HL. Histamine excites noradrenergic neurons in locus coeruleus in rats. Neuropharmacology 2005;49:129-134.
16. 3 receptors. J Neural Transm Gen Sect 1993;93:1-10.
17. 3-receptor activation inhibits dopamine synthesis in rat striatum. NeuroReport 2000;11:163-166.
18. 3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices. Neurosci Lett 2004;364:179-184.
19. Arias-Montaño JA, Floran B, Garcia M, Aceves J, Young JM. Histamine H 3 receptor-mediated inhibition of depolarization-induced, dopamine D 1 receptor-dependent release of [3H]-γ-aminobutyric acid from rat striatal slices. Br J Pharmacol 2001;133:165-171.
20. 2 receptors and the implications for striatal function. Neuropharmacology 2008;55:190-197.
21. 3 receptor antagonist, increases GABA release from the rat hypothalamus. Methods Find Exp Clin Pharmacol 1997;19:289-298.
22. Korotkova TM, Haas HL, Brown RE. Histamine excites GABAergic cells in the rat substantia nigra and ventral tegmental area in vitro. Neurosci Lett 2002;320:133-136.
23. Bergquist F, Ruthven A, Ludwig M, Dutia MB. Histaminergic and glycinergic modulation of GABA release in the vestibular nuclei of normal and labyrinthectomised rats. J Physiol 2006;577:857-868.
24. 2+ ions on N-methyl-D-aspartate (NMDA)-induced noradrenaline release in vitro. Naunyn Schmiedebergs Arch Pharmacol 1990;342:513-519.
25. Blandina P, Munari L, Provensi G, Passani MB. Histamine neurons in the tuberomamillary nucleus: A whole center or distinct subpopulations? Front Syst Neurosci 2012, Article number 33, and references herein.
26. Tiligada E, Kyriakidis K, Chazot PL, Passani MB. Histamine pharmacology and new CNS drug targets. CNS Neurosci Ther 2011;17:620-628.
27. 35S]GTPγ[S] binding in rat striatum: Evidence for additive effects but lack of interactions. Biochem Pharmacol 2007;73:1172-1181.
28. 3 receptors regulate glutamate, but not GABA release in rat thalamus. Neuropharmacology 2007;52:527-535.
29. 3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. Eur J Pharmacol 2007;563:117-123.
30. 3 receptors inhibit serotonin release in substantia nigra pars reticulata. J Neurosci 2004;24:8704-8710.
31. 3 receptor as a therapeutic drug target for CNS disorders. Drug Discovery Today 2009;14:509-515.
32. 3 receptor: An attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008;154:1166-1181.
33. 3 receptor antagonists go to clinics. Biol Pharm Bull 2008;31:2163-2181.
34. 3 antagonists as wake-promoting and pro-cognitive agents. Curr Top Med Chem 2008;8:988-1002.
35. Letavic MA, Barbier AJ, Dvorak CA, Carruthers NI. Recent medicinal chemistry of the histamine H3 receptor. Prog Med Chem 2006;44:181-206.
36. 3 receptor antagonists reach out for the clinic. Drug Discovery Today 2005;10:1613-1627.
37. Letavic MA, Aluisio L, Atack JR, et al. Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development. Bioorg Med Chem Lett 2010;20:4210-4214.
38. 3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004;13:1237-1248.
39. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004;25:618-625.
40. 3 receptor ligands and cognitive function: An overview. IDrugs 2004;7:667-673.
41. Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichie M.E. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA 2005;102:9673-9678.
42. Haas HL, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003;4:121-130.
43. 3 receptor: From gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005;4:107-120.
44. 3 receptor. Biochem Pharmacol 2007;73:1195-1204.
45. 3 receptor. Trends Pharmacol Sci 2007;28:350-357.
46. 3 receptor agonists. Mini Rev Med Chem 2004;4:955-963.
47. 3 receptor antagonists. Mini Rev Med Chem 2004;4:965-977.
48. 3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds. J Med Chem 2003;46:1523-1530.
49. 3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 2007;16:967-985.
50. 3 antagonists. Expert Opin Ther Pat 2007;17:675-687.
51. 3 antagonists. Annu Rep Med Chem 2007;42:49-62.
52. 3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Mol Interv 2006;6:77-88.
53. 3 receptor as a drug discovery target. J Med Chem 2011;54:26-53, and references herein.
54. 3 receptor antagonists. Drug Discov Today Technol 2013;10:e483-e489, and references herein.
55. 3 antagonists/inverse agonists. Biochem Pharmacol 2006;71:1103-1113.
56. 3 receptors and their role in basal ganglia physiology and pathophysiology. Sign Transduct 2007;7:364-371.
57. Leurs R, Vischer HF, Wijtmans M, De Esch IJP. En route to new blockbuster anti-histamines: Surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci 2011;32:250-257.
58. 3 receptor ligands making the final push towards the market? Expert Opin Investig Drugs 2011;20:1629-1948.
59. 3 receptors. Nature 1987;327:117-123.
60. 3 receptor agonist. J Pharmacol Exp Ther 1992;263:304-310.
61. 3 receptor. Eur J Med Chem 1992;27:511-517.
62. 3-receptor antagonist. J Pharmacol Exp Ther 1998;287:658-666.
63. 3-receptor antagonist of high oral in vivo potency with 4-(ω-(arylalkyloxy)alkyl)-1H-imidazole structure. Arch Pharm (Weinheim) 1998;331:211-218.
64. 3-receptor antagonist, of learning and memory in the elevated plus-maze test in mice. Naunyn Schmiedebergs Arch Pharmacol 1998;357:508-513.
65. Stephanos J. Drug-protein interactions: Two-site binding of heterocyclic ligands to a monomeric hemoglobin. J Inorg Biochem 1996;62:155-169.
66. 3 receptor. J Neurochem 2007;103:248-258.
67. Greasley PJ, Clapham JC. Inverse agonism or neutral antagonism at G-protein coupled receptors: A medicinal chemistry challenge worth pursuing? Eur J Pharmacol 2006;553:1-9.
68. Walter M, Stark H. Histamine receptor subtypes: A century of rational drug design. Front Biosci (Schol Ed) 2012;S4:461-488.
69. 3 receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des 2007;21:437-453.
70. Celanire S, Lebon F, Stark H. Drug discovery: From hits to clinical candidates. In: Vohora D, editor. The third histamine receptor: Selective ligands as potential therapeutic agents in CNS disorders. CRC Press, Taylor & Francis CRC Press Inc.: CRS Press, 2009;103-165.
71. Schwartz JC, Lecomte JM. Treatment of Parkinson's disease obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands, U.S. Patent 2006; EP1707203.
72. 3 antagonists for treatment of cognitive deficits in CNS diseases. Curr Top Med Chem 2010;10:153-169.
73. Black LA., Nersesian DL, Sharma P, et al. 4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration. Bioorg Med Chem Lett 2007;17:1443-1446.
74. Raddatz R, Hudkins RL, Mathiasen JR, et al. CEP-26401 (irdabisant), a potent and selective histamine H3 receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther 2012;340:124-133.
75. 3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology 2011;60:460-466.
76. 3 receptor antagonists with potent cognition enhancing activity. J Med Chem 2012;55:414-423.
77. 3 receptor antagonists: Trans - N -ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl] cyclobutanecarboxamide (PF-03654746) and trans -3-fluoro-3-[3-fluoro-4- (pyrrolidin-1-ylmethyl)phenyl]- N -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764). J Med Chem 2011;54:7602-7620.
78. 3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther 2007;320:365-375.
79. 3 receptor antagonists/inverse agonists: A patent review (2010-present). Expert Opin Ther Pat 2014;24:89-111.
80. 3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: Dose-dependent effects in the human photosensitivity model. Epilepsy Behav 2013;28:66-70.
81. 3 receptor antagonists: From target identification to drug leads. Biochem Pharmacol 2007;73:1084-1096.
82. Barbier AJ, Berridge C, Dugovic C, et al. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 2004;143:649-661.
83. 3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 2003;305:897-908.
84. Diaz JAM, Escribano BA, Martin UPE, Romanach MF. Cyclopropylmethanone derivatives, the preparation and therapeutic use thereof. Patent WO2005037810 (04/28/2005).
85. 3-receptor antagonist. Arch Pharm 2004;337:219-229.
86. Medhurst AD, Briggs MA, Bruton G, et al. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem Pharmacol 2007;73:1182-1194.
87. Investigational Drugs Database (IDdb), Thomson pharma partnering. http://partnering.thomson-pharma.com (accessed August 2009).
88. 3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007;321:1032-1045.
89. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 2011;336:38-46.
90. 3 receptor antagonists: Steric tolerance for a lipophilic side chain. Eur J Med Chem 2012;48:214-230.
91. 3 receptor inverse agonists. J Med Chem 2008;51:6889-6901.
92. 3 receptor inverse agonists. Bioorg Med Chem Lett 2008;18:6041-6045.
93. Nagase T, Sato N, Kii S, Sato K, Tsuritani T, Sawada N. Process for production of 4(3H)-quinazolinone derivative. PCT Int Appl 2006; WO 2006132424.
94. 3 receptor occupancy, a PET study in human subjects. Int J Neuropsychopharmacol 2013;16:1231-1239.
95. 3-receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav 2012;102:203-214.
96. Esbenshade TA, Browman KE, Miller TR, et al. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 2012;343:233-245.
97. Haig G, Meier A, Pritchett Y, Hall C, Gault L, Lenz R. Evaluation of the efficacy and safety of the H3 antagonist ABT-288 in mild-to-moderate Alzheimer's disease. Alzheimers Dement 2012;8:P601-P602.
98. 3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull 2014 [Epub ahead of print] DOI:10.1093/schbul/sbt240
99. 3 receptor antagonists. Bioorg Med Chem Lett 2013;23:6890-6896.
100. 3 receptor antagonist in patients with mild to moderate Alzheimer's disease: A preliminary investigation. Curr Alzheimer Res 2013;10:240-251.
101. Herring WJ, Wilens TE, Adler LA. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012;73:e891-e898.
102. Decker M. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. Mini Rev Med Chem 2007;7:221-229.
103. Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer's disease treatment. Curr Med Chem 2011;18:4949-4975.
104. Chen X, Decker M. Multi-target compounds acting in the central nervous system designed from natural products. Curr Med Chem 2013;20:1673-1685.
105. 3 receptor antagonist pharmacophore in antipsychotics serotonin receptors. Bioorg Med Chem Lett 2009;19:538-542.
106. 3 receptor antagonists as potential procognitive agents. Pharmazie 2006;61:179-182.
107. 3 receptor antagonists combining anticholinesterase activity. ChemMedChem 2010;5:1143-1149.
108. Apelt J, Ligneau X, Pertz H, et al. Development of a new class of non-imidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. J Med Chem 2002;45:1128-1141.
109. 3 receptor affinities. Bioorg Med Chem 2003;11:2163-2174.
110. Grassmann S, Apelt J, Ligneau X, et al. Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: Omega-piperidinoalkanamine derivatives. Arch Pharm (Weinheim) 2004;337:533-545.
111. 3 receptor antagonists with combined inhibitory potency at Ntau-methyltransferase: Ether derivatives. Pharmazie 2005;60:97-106.
112. 3 receptor antagonists from molecular modeling. Bioorg Med Chem 2008;16:2968-2973.
113. 3 receptor antagonists with moderate anti-cholinesterase activity. Bioorg Med Chem 2008;16:9911-9924.
114. 3 receptor antagonists. ACS Chem Neurosci 2014;5:225-242.
115. 3R and BACE 1 inhibitory activities. Bioorg Med Chem 2011;19:7158-7167.
116. Nikolic K. Theoretical study of phenolic antioxidants properties in reaction with oxygen-centered radicals. THEOCHEM 2006;774:95-105.
117. Nikolic K. QSAR study of aromatic organochalcogens with glutathione peroxidase - like antioxidant activity. QSAR Comb Sci 2007;26:358-367.
118. Nikolic K. QSAR study of α-tocopherol derivatives with chemotherapeutic activity against human breast cancer cells. THEOCHEM 2007;809:137-143.
119. Nikolic K. Design and QSAR study of analogs of alpha-tocopherol with enhanced antiproliferative activity against human breast adenocarcinoma cells. J Mol Graph Model 2008;26:868-873.
120. Nikolic K, Filipic S, Agbaba D. QSAR study of Imidazoline antihypertensive drugs. Bioorg Med Chem 2008;16:7134-7140.
121. Nikolic K, Filipic S, Agbaba D. QSAR study of selective I1-imidazoline receptor ligands. SAR QSAR Environ Res 2009;20:133-144.
122. Nikolic K, Agbaba D. Design and QSAR study of analogs of γ-tocotrienol with enhanced antiproliferative activity against human breast cancer cells. J Mol Graph Model 2009;27:777-783.
123. Nikolic K, Agbaba D. QSAR study and design of novel organoselenium and α-tocopherol derivatives with enhanced chemotherapeutic activity. Lett Drug Des Discov 2009;6:228-235.
124. Nikolic K, Agbaba D. Prediction of hepatic microsomal intrinsic clearance and human clearance values for drugs. J Mol Graph Model 2009;28:245-252.
125. Nikolic K, Filipic S, Agbaba D. Multi-Target QSAR and docking study of steroids binding to corticosteroid-binding globulin and sex hormone-binding globulin. Curr Comput Aided Drug Des 2012;8:296-308.
126. Nikolic K, Agbaba D. Pharmacophore development and SAR studies of imidazoline receptor ligands. Mini Rev Med Chem 2012;12:1542-1555.
127. Nikolic K, Veljkovic N, Gemovic B, Srdic-Rajic T, Agbaba D. Imidazoline-1 receptor ligands as apoptotic agents: Pharmacophore modeling and virtual docking study. Comb Chem High Throughput Screen 2013;16:298-319.
128. Ivkovic BM, Nikolic K, Ilic BB, et al. Phenylpropiophenone derivatives as potential anticancer agents: Synthesis, biological evaluation and quantitative structure-activity relationship study. Eur J Med Chem 2013;63:239-255.
129. Filipic B, Nikolic K, Filipic S, et al. Identifying the CmbT substrates specificity by using a quantitative structure-activity relationship (QSAR) study. J Taiwan Inst Chem Eng 2014;45:764-771.
130. Nikolic K, Filipic S, Smoliński A, Kaliszan R, Agbaba D. Partial least square and hierarchical clustering in ADMET modeling: Prediction of blood - brain barrier permeation of α-adrenergic and imidazoline receptor ligands. J Pharm Sci 2013;16:622-647.
131. 3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution. Mol Med Rep 2012;5:1043-1048.
132. Quraishi S, Frangou S. Neuropsychology of bipolar disorder: A review. J Affect Disord 2002;72:209-226.
133. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-225.
134. Fava GA, Fabbri S, Sonino N. Residual symptoms in depression: An emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1019-1027.
135. Milan M. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370.
136. 3 ligands: Optimization of the H3 pharmacophore. Bioorg Med Chem Lett 2007;17:702-706.
137. 3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett 2007;17:1047-1051.
138. 3 receptor antagonist and serotonin reuptake inhibitor. Eur J Pharmacol 2007;576:43-54.
139. 3 antagonist and serotonin transporter inhibitors. Bioorg Med Chem Lett 2007;17:2603-2607.
140. 3 antagonists and serotonin reuptake transporter inhibitors. Bioorg Med Chem Lett 2007;17:2566-2569.
141. 3 antagonists with serotonin reuptake inhibitor activity. Bioorg Med Chem Lett 2007;17:3130-3135.
142. 3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett 2007;17:4799-4803.